Literature DB >> 9554741

Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland.

S E Olufemi1, J S Green, P Manickam, S C Guru, S K Agarwal, M B Kester, Q Dong, A L Burns, A M Spiegel, S J Marx, F S Collins, S C Chandrasekharappa.   

Abstract

Familial multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder with affected individuals developing parathyroid, gastrointestinal (GI) endocrine, and anterior pituitary tumors. Four large kindreds from the Burin peninsula/Fortune Bay area of Newfoundland with prominent features of prolactinomas, carcinoids, and parathyroid tumors (referred to as MEN1Burin) have been described, and they show linkage to 11q13, the same locus as that of MEN1. Haplotype analysis with 16 polymorphic markers now reveals that representative affected individuals from all four families share a common haplotype over a 2.5 Mb region. A nonsense mutation in the MEN1 gene has been found to be responsible for the disease in the affected members in all four of the MEN1Burin families, providing convincing evidence of a common founder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554741     DOI: 10.1002/(SICI)1098-1004(1998)11:4<264::AID-HUMU2>3.0.CO;2-V

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  19 in total

1.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

3.  A founder effect in the newfoundland population reduces the Bardet-Biedl syndrome I (BBS1) interval to 1 cM.

Authors:  T L Young; M O Woods; P S Parfrey; J S Green; D Hefferton; W S Davidson
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

4.  New Concepts About Familial Isolated Hyperparathyroidism.

Authors:  Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2019-03-08       Impact factor: 5.958

Review 5.  The MEN1 gene and associated diseases: an update.

Authors:  T Tsukada; K Yamaguchi; T Kameya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies.

Authors:  R C Green; J S Green; S K Buehler; J D Robb; D Daftary; S Gallinger; J R McLaughlin; P S Parfrey; H B Younghusband
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 7.  Multiple endocrine neoplasia type 1Burin from Mauritius: a novel MEN1 mutation.

Authors:  C Kong; S Ellard; C Johnston; N R Farid
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

8.  Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1).

Authors:  Koen Ma Dreijerink; Cees Jm Lips
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

9.  Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders.

Authors:  S Giraud; C X Zhang; O Serova-Sinilnikova; V Wautot; J Salandre; N Buisson; C Waterlot; C Bauters; N Porchet; J P Aubert; P Emy; G Cadiot; B Delemer; O Chabre; P Niccoli; F Leprat; F Duron; B Emperauger; P Cougard; P Goudet; E Sarfati; J P Riou; S Guichard; M Rodier; A Meyrier; P Caron; M C Vantyghem; M Assayag; J L Peix; M Pugeat; V Rohmer; M Vallotton; G Lenoir; P Gaudray; C Proye; B Conte-Devolx; P Chanson; Y Y Shugart; D Goldgar; A Murat; A Calender
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 10.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.